Filing Flows › Lineage Cell Therapeutics (LCTX) › Q1 2025
Lineage Cell Therapeutics (LCTX) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 13, 2025
Lineage Cell Therapeutics (LCTX) reported revenue of $1.5M for the first quarter 2025 (Q1 2025), +4% from a year earlier and -48% from the quarter before. Operating margin was -433.1%, net loss $4.1M (275.8% of revenue).
Lineage Cell Therapeutics, Q1 2025: revenue $1.5M (+4% year over year), operating margin -433.1%, net loss $4.1M, operating cash flow −$4.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.5M | -48% | +4% |
| Operating profit | −$6.5M | — | — |
| Net earnings | −$4.1M | — | — |
| Operating cash flow | −$4.9M | — | — |
What changed
Revenue was $1.5M in Q1 2025, up 4% year over year and down 48% from the previous quarter. Collaboration Revenues was the largest line at 85% of revenue. Collaboration Revenues added $83K year over year (up 7%), 143% of the total change. Royalties License and Other Revenues declined 10%.
Operating costs exceeded revenue by $6.5M, an operating margin of -433.1%. Total costs fell 1% while revenue rose 4%. The quarter ended with a net loss of $4.1M, wider than the previous quarter's $3.2M loss. Minority interests bore $4K of it: to shareholders the quarter was a loss of $4.1M. Non-operating items added $2.4M, -57% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$4.9M. Non-cash charges added back $164K of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items used $2.1M. Capital expenditures of $97K exceeded it, leaving free cash flow of −$5.0M.
Questions
What was Lineage Cell Therapeutics' revenue in the first quarter 2025?
Lineage Cell Therapeutics (LCTX) reported revenue of $1.5M for the first quarter 2025 (Q1 2025), +4% from a year earlier and -48% from the quarter before.
Was Lineage Cell Therapeutics profitable in the first quarter 2025?
Operating loss was $6.5M (-433.1% of revenue) and net loss $4.1M.